859 results about "Platelet" patented technology

The invention relates to the technical field of target detection, and discloses a blood cell detection method based on improved YOLOv8. According to the method, a convolutional attention module (CBAM) is introduced, so that the detection performance of the model on a shielded small target is improved; a new loss function S-MPDIOU is set, so that the accuracy and robustness of the loss function are further improved; the multi-scale feature fusion technology is adopted to better capture blood cell information of different sizes, so that the model can more accurately identify small target platelets; the recall rate is improved by improving a non-maximum suppression (NMS) algorithm, and particularly under the condition of dense blood cells or complex forms, the improved NMS algorithm can more effectively solve the overlapping problem and reduce false detection and missing detection. Through testing, the model can accurately identify and position different types of blood cells such as red blood cells, white blood cells and blood platelets in an image, and a new effective method is provided for blood cell detection.

An optical detection assembly for monitoring a fluid includes a light source, a light detector array, and a controller. The controller receives signals from the light detector array that are indicative of the intensity of light received by the light detector array after the light has passed through the fluid. The controller generates a scattering profile based on the signals, with the scattering profile including rising and falling edges each having a slope. The controller calculates one or both slopes and determines the platelet mass index (for a platelet-containing fluid) and / or the concentration of a substance in the fluid based on said slope(s). The optical detection assembly may also be used to analyze a reference fluid having a known concentration of the substance, with signals received by the controller when analyzing the reference fluid being a factor when determining the concentration of the substance in the fluid of interest.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a targeted liposome as an active component in preparation of a medicine for treating ischemic brain injury. The targeted lipidosome for treating cerebral arterial thrombosis is prepared by fusing the lipidosome and the platelet-neutrophil aggregate membrane, realizes efficient and specific targeting of an ischemic brain region, effectively reduces brain tissue infarction and damage of a new region, relieves brain inflammation through multi-channel regulation and control, and improves the cerebral arterial thrombosis treatment effect. The compound can be used as an active ingredient for preparing a medicine for treating ischemic brain injury. And after the target liposome is further coated with a rutin drug, the synergistic treatment effect is realized. The liposome medicine can be used as an active component and has a good application prospect in treatment of ischemic brain injury diseases.

The invention discloses a kit and a method for HLA cross reaction group and HPA genotyping. The system for HLA cross reaction group and HPA genotyping detection is obtained through respective combination design of two different primers on the basis of common specific SNP loci, and rapid, simple, low-cost and high-throughput HLA epitope and HPA genotyping detection can be realized, so that platelet infusion ineffectiveness and immune platelet infusion ineffectiveness are more effectively prevented.

A triple droplet type digital PCR (ddPCR) detection method for the severe fever with thrombocytopenia syndrome virus (SFTSV), spotted heat group rickettsia (SFGR) and tsutsugamushi Ot is established. According to the method, specific primers and probes are designed based on an SFTSV L gene, an SFGR 17Kd gene and an Ot 47Kd htrA gene, the reaction temperature and the concentration of the primers and probes are optimized to establish an SFTSV, SFGR and Ot triple ddPCR reaction system, and the specificity, sensitivity and repeatability of the triple ddPCR reaction system are analyzed. According to results, the optimal primer concentration and probe concentration of triple digital PCR are 600nmol / L and 250nmol / L respectively, and the optimal annealing temperature is 60 DEG C; the correlation coefficients of the triple ddPCR SFTSV, the triple ddPCR SFGR and the triple ddPCR Ot standard curve are 0.98, 0.99 and 0.98 respectively, and the lowest detection lower limits are 0.59 copies / mu L, 0.46 copies / mu L and 0.36 copies / mu L respectively. According to the invention, the SFTSV, SFGR and Ot triple digital PCR detection method is established, the sensitivity is high, the specificity is strong, and quantitative detection of three pathogens in SFTS suspected cases can be realized.

A type of additive based on a fluorinated carbamate prepolymer, a preparation method therefor, and a use thereof in the preparation of a medical fluorinated anticoagulant polyurethane material. The preparation method of the additive comprises: reacting a polyester / polyether diol, a diisocyanate and a fluorinated small-molecule diol, to obtain a carbamate prepolymer having an isocyanate end group, and then capping with a monohydric alcohol having a fluorinated carbon chain, to obtain an additive based on a fluorinated carbamate prepolymer. The additive has a high fluorine content. After being blended with a polyurethane masterbatch, fluorine atoms having low surface energy can be enriched on the surface of the material, and the fluorine atom content on the surface of the material can be as high as 60%. This effectively reduces the adhesion of plasma proteins, cells and platelets on the surface of the material, providing the medical polyurethane material with an excellent anticoagulant effect. In addition, it maintains the excellent mechanical properties of polyurethane, and is thus widely applicable in the preparation of medical fluorinated anticoagulant polyurethane materials.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

Provided herein are compositions comprising allogeneic human plasma and platelet derived product, and methods for making the compositions and using the compositions as a therapeutic for example, in orthopedic indications.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The invention provides a diagnostic marker for systemic lupus erythematosus and application of the diagnostic marker, and belongs to the technical field of biological medicine. The diagnostic marker is at least one protein of PDGFA (Platelet Derivative Growth Factor Amplification), APOD (Adenosine Polymerase Chain Reaction), CFHR5, AMDHD1 and SCGB3A1; the amino acid sequence of the PDGFA is as shown in SED ID NO. 1; the amino acid sequence of the APOD is as shown in SED ID NO. 2; the amino acid sequence of the CFHR5 is as shown in SED ID NO.3; the amino acid sequence of AMDHD1 is as shown in SED ID NO. 4; and the amino acid sequence of the SCGB3A1 is as shown in SED ID (Sequence of Identification) NO.5. According to the present invention, the five proteins are adopted as the SLE disease diagnosis biomarker independently or in the combination manner, such that advantages of high accuracy, high sensitivity and high specificity are provided, and the new target spot is provided for the diagnosis, the intervention improvement and the like of the SLE patient.

The invention belongs to the technical field of medical equipment, and particularly relates to a blood growth factor extraction device and an information loading system.The blood growth factor extraction device comprises a box body used for connecting all components; the blood centrifugal assembly is arranged in the box body, and the blood centrifugal assembly is used for centrifugally removing red blood cells of the blood; the information field assembly is arranged in the box body, the information field assembly is connected with the blood centrifugal assembly, and the information field assembly is used for performing scalar wave action on blood in the blood centrifugal assembly and loading specific life factor information into plasma; the disinfection assembly is arranged in the box body, the disinfection assembly is connected with the blood centrifugal assembly, the disinfection assembly is used for disinfecting test tubes in the blood centrifugal assembly, and it is guaranteed that wound repair factors, blood platelets, growth factors and the like are more easily and sufficiently separated during separation and preparation.

The invention provides a platelet membrane bionic nano-drug delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, through membrane engineering modification, a wrapping material obtained through hybridization of a platelet membrane and an NK cell exosome is used for loading ginsenoside Rg3 for the first time, a ginsenoside Rg3 delivery system with high encapsulation efficiency and high drug loading capacity is obtained, and the system has excellent stability and can be stored for a long time in normal-temperature and high-temperature environments; the ginsenoside Rg3-loaded platelet membrane bionic nano-drug delivery system is simple in preparation method and suitable for wide popularization and application; according to the ginsenoside Rg3-loaded platelet membrane bionic nano-drug delivery system, the lung cancer treatment effect of ginsenoside Rg3 can be effectively improved, a novel drug is provided for lung cancer treatment, and the drug is high in safety, high in biocompatibility, free of adverse reaction in the treatment process and obvious in anti-inflammatory effect.

The invention relates to the technical field of hemostatic materials, in particular to a clay mineral-based aerogel hemostatic material and a preparation method thereof. The invention discloses a preparation method of a clay mineral-based aerogel hemostatic material. The preparation method comprises the following steps: S1, uniformly dispersing clay minerals and sodium alginate in deionized water respectively, and stirring to prepare slurry and sol for later use; s2, uniformly mixing the slurry and the sol, preparing a mixed sol, introducing the mixed sol into a mold, dropwise adding a proper amount of a metal salt solution, and standing to obtain a standing product; s3, freeze-drying the standing product to obtain the clay mineral-based aerogel hemostatic material. The composite material disclosed by the invention combines the adsorbability of clay and the biocompatibility of sodium alginate, has excellent biocompatibility and high safety, and shows excellent performance in the aspects of absorbing and concentrating tissue fluid, and the composite aerogel can quickly activate platelets and stimulate blood coagulation factors to efficiently coagulate blood, and has efficient hemostasis capability.

The present invention relates to the technical field of diabetes, and in particular to a controlled-release diabetic wound healing promoting treatment method, comprising the following treatment experimental steps: step S1: preparation of Hst1@PNPs; step S2: Coomassie brilliant blue staining; step S3: scanning and transmission electron microscopy detection; in the present invention, a slow-release Hst1 treatment method is constructed by encapsulating Hst1 into platelet membrane vesicles derived from autologous blood. On the one hand, the PNPs encapsulate the linear Hst1 peptide structure to prevent it from being rapidly degraded by high proteases in diabetic wound exudate, thereby improving bioavailability. On the other hand, the PNPs can adsorb excess LPS in the wound exudate, and cooperate with Hst1 to achieve anti-inflammatory and anti-oxidative stress effects. Subsequent cell and animal experiments further confirmed that Hst1@PNPs have the effects of anti-inflammatory, scavenging ROS, promoting re-epithelialization, collagen deposition and angiogenesis, thereby promoting diabetic wound healing.

The invention provides a method for generating platelet-like particles based on MEG-01 cells and evaluating functions of the platelet-like particles, and belongs to the technical field of cell biology. The invention provides a method for generating PLPs by inducing MEG-01 cells. According to the method, the MEG-01 cells are differentiated into PLPs with platelet characteristics by utilizing a PMA inducer. The PLPs disclosed by the invention has characteristic surface marker expression consistent with that of natural platelets, can respond to stimulation of an activator ADP, and shows biological functional characteristics of the platelets. The method for generating PLPs is simple and economical, experimental conditions are highly controllable, and an economical, efficient and repeatable in-vitro model is provided for functional research related to platelets.

The monoclonal antibody of the glycoprotein Gn of the severe fever with thrombocytopenia syndrome virus is screened on the basis of immune repertoire sequencing, and the biological characteristics of the monoclonal antibody are identified. The method comprises the following steps: taking purified SFTSV-Gn as bait, taking virus specific B cells from an immunized female BALB / c mouse B cell bank, selecting an antibody sequence with potential binding activity by utilizing a 10 * immune repertoire sequencing method in combination with bioinformatics analysis, constructing the antibody sequence to an eukaryotic expression vector pcDNA3.4, expressing and purifying a monoclonal antibody, and identifying the biological activity of the monoclonal antibody. 14 antibodies are selected from 3544 captured B cells, functional verification shows that 12 antibodies can be combined with SFTSV-Gn glycoprotein, and the Gn-5 antibody and the Gn-7 antibody have high combining capacity; western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize the SFTSV, the effective concentration is as low as 2 mu g / mL, and a foundation is laid for development of a rapid diagnosis reagent for the SFTSV.

The present invention provides a use of a purified platelet-derived exosome dry powder for relieving inflammation or injury, wherein the number of platelet-derived exosomes in each gram of the purified platelet-derived exosome dry powder is more than or equal to 1×1010.

The invention discloses a traditional Chinese medicine composition with an effect of improving artery blood vessel plaque and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problem to be solved is to provide a traditional Chinese medicine composition capable of improving vascular plaques such as carotid artery, aortic arch, brachial trunk, subclavian artery and the like aiming at the current situation that adverse reactions exist when statin lipid-lowering drugs and antiplatelet drugs are taken for a long time to treat artery vascular plaques. According to the technical scheme, the traditional Chinese medicine composition with the effect of improving the artery blood vessel plaque is characterized by comprising radix puerariae, red yeast rice, folium cortex eucommiae, hippophae rhamnoides leaves and natto.

Disclosed are platelet-derived extracellular vesicles (EVs), and composite materials comprising them, for use as bone replacement material and / or as bone rebuilding material. Also, methods of production, medical uses and kits are disclosed.

Provided herein is a method for the screening of patients with at-risk MASH (metabolic dysfunction-associated steatohepatitis, formerly named nonalcoholic steatohepatitis or NASH). The combination of levels of five circulating markers, i.e. alanine aminotransferase (ALAT), aspartate transaminase (ASAT), platelets, hsa-miR-34a and YKL-40 in a subject, and eventually the age and gender of said subject, allows to accurately identify non-cirrhotic at-risk MASH. The information obtained from the levels of these markers also allows to screen a subject as being eligible to liver biopsy and / or to classify a subject as a receiver or non-receiver of a treatment of MASH and / or to classify a subject as a responder or non-responder of a treatment of MASH.

The present invention provides a use of a purified platelet-derived exosome dry powder for relieving inflammation or injury, wherein the number of platelet-derived exosomes in each gram of the purified platelet-derived exosome dry powder is more than or equal to 1×1010.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The present disclosure relates to methods for making platelet derived human growth factor concentrate and related therapeutic and pharmaceutical compositions and uses thereof. Methods of use of the therapeutic and pharmaceutical compositions are also provided herein.

The invention discloses a preparation method of a thermo-sensitive collagen-chitosan composite gel and an application of the thermo-sensitive collagen-chitosan composite gel. The preparation method of the thermo-sensitive collagen-chitosan composite gel comprises the following steps: dissolving hydroxybutyl chitosan and / or hydroxypropyl chitosan and recombinant I-type collagen in water at the temperature of 2 to 5 DEG C, so as to obtain the thermo-sensitive collagen-chitosan composite gel, the amino acid sequence of the recombinant I type collagen is an amino acid sequence obtained by repeating a short amino acid sequence as shown in SEQ ID No: 1 (GAPGAPGSQGAPGLQ) for 52 times. In the thermo-sensitive collagen-chitosan composite gel prepared by the preparation method disclosed by the invention, the recombinant I-type collagen is self-assembled to form collagen fibers which are more beneficial to aggregation and solidification of platelets and can act on a wound surface for a longer time, so that the thermo-sensitive collagen-chitosan composite gel has a better hemostatic effect and a better wound surface healing effect.

The application belongs to the technical field of biomedical engineering, and particularly relates to a micro-hydrogel wrapping platelets, a freeze-dried powder and a preparation method, use method and application thereof. The micro-hydrogel wrapping platelets, the micro-hydrogel is in a core-shell or multi-chamber structure, and the platelets are wrapped inside; the micro-hydrogel is formed by emulsifying a dispersed phase solution in a continuous phase solution and spontaneously physically gelling, and the platelets are wrapped inside; the micro-hydrogel can reduce the damage to the platelets caused by the freeze-drying process and rehydration, and the platelets can be stored for a long time after freeze-drying; when used, the micro-hydrogel can be dissociated by only rehydrating, centrifuging and heating, without the need of adding an additional decrosslinking agent, and the operation is convenient. The micro-hydrogel wrapping platelets has higher expression of hemostasis-related glycoprotein and lower de-sialylation degree after freeze-drying, rehydration and dissociation, and is expected to have better hemostasis ability and longer in-vivo circulation time; and is expected to greatly extend the storage time of platelets and alleviate the shortage of platelets.

The invention is applicable to the technical field of cell engineering, and provides a mitochondria-enhanced dental pulp mesenchymal stem cell and a preparation method and application thereof, and the preparation method comprises the following steps: co-culturing platelet-rich fibrin and dental pulp mesenchymal stem cells by using a Transwell chamber to obtain the mitochondria-enhanced dental pulp mesenchymal stem cell. The platelet-rich fibrin transmits mitochondria to the dental pulp mesenchymal stem cells to improve the regeneration capacity of the dental pulp mesenchymal stem cells. According to the invention, an autologous platelet enrichment, namely platelet-rich fibrin, is used as a mitochondria donor with a respiratory function, mitochondria is continuously transferred to the dental pulp-derived mesenchymal stem cells through a cell bioengineering technology, and the mitochondria-enhanced dental pulp mesenchymal stem cells are constructed and applied to tissue damage repair; the vascular regeneration regulation and control capability of the dental pulp mesenchymal stem cells is obviously improved, and the existing mesenchymal stem cell treatment technology is obviously improved.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a thrombopoietin peptidomimetic peptide diagram detection and analysis method which comprises the following steps: (1) performing buffer system replacement on thrombopoietin peptidomimetic through ultrafiltration centrifugation; (2) carrying out enzymolysis on the thrombopoietin peptidomimetic by adopting trypsin; and (3) detecting and analyzing the enzymolysis peptide fragment by using a reversed-phase high-performance liquid chromatography. The method disclosed by the invention has the beneficial effects that sample concentration and buffer solution replacement are performed through the ultrafiltration tube, and the sample subjected to enzymolysis is high in purity and can be directly detected by using reversed-phase high-performance liquid chromatography, so that the method for detecting and analyzing the peptide diagram of the thrombopoietin peptidomimetic is simple and convenient to operate, and the detection efficiency of thrombopoietin peptidomimetic drugs is improved; by controlling the chromatographic conditions, the accuracy and precision of high performance liquid chromatography detection are improved, and the quality analysis and control of thrombopoietin peptidomimetic drugs can be realized.

Disclosed are platelet-derived extracellular vesicles (EVs), and composite materials comprising them, for use as bone replacement material and / or as bone rebuilding material. Also, methods of production, medical uses and kits are disclosed.